A primary aim of pneumococcal immunisation programmes is to prevent invasive pneumococcal disease (IPD), defined as infection of Streptococcus pneumoniae in the blood or other normally sterile sites, with associated hospitalisations and deaths. Pneumococci also cause respiratory tract infections without bacteraemia; the most severe of which is pneumococcal pneumonia, but also include middle-ear infection (acute otitis media) and sinusitis.
We aimed to evaluate the safety of maternal Tdap; thus, we assessed health events by examining the difference in birth and hospital-related outcomes of infants with and without fetal exposure to Tdap. This was a retrospective cohort study using linked administrative datasets. The study population were all live-born infants in New Zealand (NZ) weighing at least 400 g at delivery and born to women who were eligible for the government funded, national-level vaccination program in 2013. Infants were followed from birth up to one year of age.
The Strategic Advisory Group of Experts (SAGE) on Immunization met on 23–25 October 2018. This report summarises the discussions, conclusions and recommendations.
Hospitalization rates for infectious diseases in New Zealand (NZ) children have increased since 1989. The highest burden is among Māori and Pacific children, and the most socioeconomically deprived. NZ introduced pneumococcal conjugate vaccine (PCV)7 in June 2008, PCV10 in 2011 and PCV13 in 2014.
The Strategic Advisory Group of Experts (SAGE) on immunization met on 17–18 April 2018. This report summarises the discussions, conclusions and recommendations.